Stock Track | Integra LifeSciences Soars 5.44% as Q4 Earnings Beat Estimates, Guidance Shows Growth Potential

Stock Track

Feb 25, 2025

Integra LifeSciences Holdings Corp. (IART) saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.

The medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share (EPS) of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.

While revenue for the quarter fell slightly short of expectations at $442.65 million versus the estimated $445.15 million, the company provided an optimistic outlook for the fiscal year 2025. Integra LifeSciences expects revenue to be in the range of $1.65 billion to $1.72 billion, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105088443"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105088443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105088443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105088443","market":"hk","top_or_hot":-1,"title":"Stock Track | Integra LifeSciences Soars 5.44% as Q4 Earnings Beat Estimates, Guidance Shows Growth Potential","media":"Stock Track","content":"<p>Integra LifeSciences Holdings Corp. (IART) saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.</p>\n\n<p>The medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share (EPS) of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.</p>\n\n<p>While revenue for the quarter fell slightly short of expectations at $442.65 million versus the estimated $445.15 million, the company provided an optimistic outlook for the fiscal year 2025. Integra LifeSciences expects revenue to be in the range of $1.65 billion to $1.72 billion, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Integra LifeSciences Soars 5.44% as Q4 Earnings Beat Estimates, Guidance Shows Growth Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Integra LifeSciences Soars 5.44% as Q4 Earnings Beat Estimates, Guidance Shows Growth Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Integra LifeSciences Holdings Corp. (IART) saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.</p>\n\n<p>The medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share (EPS) of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.</p>\n\n<p>While revenue for the quarter fell slightly short of expectations at $442.65 million versus the estimated $445.15 million, the company provided an optimistic outlook for the fiscal year 2025. Integra LifeSciences expects revenue to be in the range of $1.65 billion to $1.72 billion, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IART","symbol_name":"英特格拉生命科学","start_time":0,"source_url":"","article_id":"1105088443","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105088443","pubTimestamp":1740495335,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Integra LifeSciences Holdings Corp.  saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.The medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share  of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.While revenue for the quarter fell s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IART":"英特格拉生命科学"},"translate_title":"股票跟踪Integra LifeSciences飙升5.44%，第四季度盈利超出预期，指引显示增长潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IART":1},"content_text":"Integra LifeSciences Holdings Corp. (IART) saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.\nThe medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share (EPS) of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.\nWhile revenue for the quarter fell slightly short of expectations at $442.65 million versus the estimated $445.15 million, the company provided an optimistic outlook for the fiscal year 2025. Integra LifeSciences expects revenue to be in the range of $1.65 billion to $1.72 billion, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}